
TEM Stock Forecast & Price Target
TEM Analyst Ratings
Bulls say
Tempus AI Inc. has demonstrated robust financial performance with a 35.9% year-over-year revenue growth, largely attributed to a 30.6% increase in Genomics revenue and a 44.6% increase in Data & Other segments. The company reported a net revenue retention (NRR) rate of approximately 140% in 2024, indicating a strong demand for its data solutions, despite management's caution regarding its sustainability. Additionally, the total contract value for data and services has reached around $940 million, signifying an increase in the company's market presence and the perceived value of its offerings in the healthcare data landscape.
Bears say
Tempus AI Inc. faces a challenging outlook following preliminary Q4 results that fell slightly below expectations, prompting a revenue forecast for FY24 to be revised down to approximately $693 million, down from previous guidance of $700 million. Additionally, potential declines in reimbursement rates and the risk of losing market share in genomic testing could further hinder the company's growth and ability to effectively monetize its dataset. Although the company's shares are currently trading at a discount compared to peer groups, these fundamental issues create significant uncertainties regarding Tempus's financial stability and future performance.
This aggregate rating is based on analysts' research of Tempus AI Inc and is not a guaranteed prediction by Public.com or investment advice.
TEM Analyst Forecast & Price Prediction
Start investing in TEM
Order type
Buy in
Order amount
Est. shares
0 shares